At 10:44 am, the stock was trading 3 per cent higher at Rs 412 on the BSE, as compared to 0.74 per cent rise in the S&P BSE Sensex. The trading volumes on the counter more-than-doubled with a combined 2.23 million equity shares changing hands on the NSE and BSE, so far.
In the July-September quarter (Q2FY21), the company’s revenue from operations grew by 22.7 per cent year-on-year (YoY) mainly on an account of new launches and increase in market share of existing products across the three verticals.
Ebitda (earnings before interest, taxes, depreciation, and amortization) for the quarter grew 78.6 per cent YoY, with a +935 basis points (bps) margin expansion YoY on changing product mix and improved operational efficiencies arising out of higher capacity utilization.
The management expects sales to Europe and LATAM over FY20-23 to expand 800bps and 400bps respectively to 28 per cent and 12 per cent. It plans to launch newer products and enter newer markets within these regions.
Near-term growth is likely to be driven by the foray into MUPS (multi-unit pellet system) products, entry into newer markets and capacity addition in PFIs (pharmaceutical formulations intermediates) . Beyond which, its US pipeline and oncology products would drive growth, analyst at Anand Rathi Share and Stock Brokers said in result update. The brokerage firm has ‘buy’ rating on the stock with target price of Rs 455 per share.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU